PrecisionLife has partnered with healthcare center the Metrodora Institute to jumpstart the diagnosis and treatment options for a range of chronic diseases including long COVID, ME/CFS, ALS and Sjögren's syndrome.
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and the Flow Cytometry Facility at the Babraham Institute have announced a collaboration to develop a bespoke cell phenotyping...
We sat down with Cary Claiborne, CEO and president of Adial Pharma, to discuss the challenges of treating alcohol abuse and company's solution – a serotonin-3 receptor antagonist that could affect neurotransmitters like dopamine and modulate the...
Sofia Baig is the president of clinical solutions at Precision for Medicine. As a strategic industry leader, she is adept driving organizational change and delivering top- and bottom-line growth.
Glox Therapeutics, a company developing precision antibiotic therapies based on naturally occurring bacteriocins, has raised £4.3m in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
Ever since injections promising to help people lose weight hit the shelves, interest around the world has been phenomenal. So high was demand, companies were finding it difficult to keep up with the demand.
PrecisionLife, a computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other...
PrecisionLife, a techbio company driving precision medicine in complex chronic diseases, has announced a data access agreement with the University of Oxford to spearhead new treatments for endometriosis.
Mursla Bio will present its novel tissue-specific Extracellular Vesicle (EV) isolation technology NEXPLOR at the International Society for Extracellular Vesicles (ISEV) annual meeting.
Engine Biosciences, a Singapore- and Silicon Valley-based company with an artificial intelligence-enabled technology platform that is designed to discover new biology targets and disease-causing links amongst known targets, has generated US$43m in a Series...
Genentech will collaborate with biopharma company Parvus to manufacture and commercialize Navacim therapeutics for the treatment of autoimmune disease.
